PHARMACY

Physicians Reference Lab develops commercial test for HPV

BY Drew Buono

OVERLAND PARK, Kan. Physicians Reference Laboratory has developed a test to detect the human papillomavirus, the cause of nearly all cervical cancer, according to published reports.

The company said it would market the test under the name COMPLeTe Care HPV. The test enables early detection of and differentiation among all 15 high-risk types of HPV, which can lead to cervical cancer.

The new test was developed under the direction of Pradip Manna, director of molecular diagnostics for Physicians Reference Laboratory. Its ability to detect the genomic variants of each high-risk HPV type will help physicians manage patients’ risk of developing cervical cancer, according to the company.

“Women of all ages will benefit from COMPLeTe Care HPV,” Spencer Kerley, chief executive officer of Physicians Reference Laboratory, said. “In addition to early detection, type differentiation can lead to higher success rates for HPV vaccines.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Parata launches PACMED C30 packaging technology

BY Drew Buono

DURHAM, N.C. Parata Systems has launched its new product, the PACMED C30, which is a packaging technology used to extend the safety and convenience of its onePAC packaging system.

onePac is a strip that contains information like patients’ medications, patient names, pill descriptions and time of day to take a dose of the medication. On the strip, up to 19 lines of information can be held. The goal of the strips are to remind patients who take multiple medications when to take what medications and how much of each medication.

The PACMED C30 expands on the technology of the onePAC by combining multiple onePAC strips together for easy access by patients. PACMED C30 is efficient and accurate, generating up to 60 unit-dose or 50 multi-dose packages a minute.

“Adherence is a critical touch point in the circle of pharmacy care, and Parata’s launch of PACMED C30 offers an exciting new way for pharmacies to extend their care by improving patient adherence, safety and convenience,” says Tom Rhoads, executive vice president for customer and market strategies at Parata Systems.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Teva announces availablility of generic Fosamax

BY Drew Buono

NORTH WALES, Pa. Teva has announced the introduction and availability of alendronate sodium tablets.

This is the generic version of the osteoporosis drug Fosamax by Merck. The drug will be available in 5 mg, 10 mg, 35 mg, 40 mg and 70 mg strengths.

“Our customers count on Teva for a continuous supply of new generic products,” stated John Denman, vice president of sales and marketing. “With the launch of alendronate sodium tablets, we add another quality product to our broad line of affordable generic pharmaceuticals.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES